Fawzi F Abu Rous, MD, discusses evolving strategies for HER2 and MET testing in non–small cell lung cancer.
Fawzi F Abu Rous, MD
Advertisement
Fawzi F Abu Rous, MD, is a thoracic medical oncologist at Henry Ford Health.
Articles by Fawzi F Abu Rous, MD
Fawzi F Abu Rous, MD, discusses the need for reliable predictive biomarkers for therapeutic development in squamous cell carcinoma of the lung.
Advertisement
Latest Updated Articles
Dr Abu Rous on the Timing of HER2 and MET Testing in NSCLCAugust 22nd 2025
Advertisement
Advertisement
Trending on OncLive
1
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
2
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
3
Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC
4
Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in Cisplatin-Ineligible MIBC
5